Sarah Ketterer
Causeway Capital Management
Sarah Ketterer Boston Scientific Corp stake
total: 372
Causeway Capital Management BSX trades
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Sarah Ketterer holds 720,339 Boston Scientific Corp (BSX) shares with a market value of roughly $30.74M accounting for 0.33% of the overall portfolio. To date, the estimated cost basis is nearly $42.68 for "buy" trades. Causeway Capital Management first purchased BSX in 2026 Q2, initially acquiring 720,339 shares.
When did Sarah Ketterer buy Boston Scientific Corp (BSX)?
Sarah Ketterer first invested in Boston Scientific Corp (BSX) in 2026 Q2 at the reported quarter-end price of $42.68 per share.
What's the cost basis of Causeway Capital Management's BSX stake?
The estimated cost basis for Boston Scientific Corp (BSX) stake is around $42.68 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $42.68
Sarah Ketterer's historical trades in Boston Scientific Corp
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.33%
|
720,339
|
$42.68
|
$30,744,061
|
new
|
+0.33%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.